Switch theme
Sign up to access all valuation multiples
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
2007
74
LTM Revenue $0.2M
Last FY EBITDA -$45.6M
$2.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
InflaRx has a last 12-month revenue (LTM) of $0.2M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, InflaRx achieved revenue of $0.2M and an EBITDA of -$45.6M.
InflaRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See InflaRx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | XXX | $0.2M | XXX | XXX | XXX |
| Gross Profit | -$3.2M | XXX | -$3.2M | XXX | XXX | XXX |
| Gross Margin | -2100% | XXX | -1901% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$45.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27477% | XXX | XXX | XXX |
| EBIT | -$69.1M | XXX | -$53.0M | XXX | XXX | XXX |
| EBIT Margin | -45927% | XXX | -31974% | XXX | XXX | XXX |
| Net Profit | -$60.8M | XXX | -$46.1M | XXX | XXX | XXX |
| Net Margin | -40425% | XXX | -27785% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, InflaRx's stock price is $1.
InflaRx has current market cap of $58.5M, and EV of $2.9M.
See InflaRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9M | $58.5M | XXX | XXX | XXX | XXX | $-0.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, InflaRx has market cap of $58.5M and EV of $2.9M.
InflaRx's trades at 17.8x EV/Revenue multiple, and -0.1x EV/EBITDA.
Equity research analysts estimate InflaRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
InflaRx has a P/E ratio of -1.1x.
See valuation multiples for InflaRx and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58.5M | XXX | $58.5M | XXX | XXX | XXX |
| EV (current) | $2.9M | XXX | $2.9M | XXX | XXX | XXX |
| EV/Revenue | 22.8x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.1x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | -1.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInflaRx's last 12 month revenue growth is 506%
InflaRx's revenue per employee in the last FY averaged $2K, while opex per employee averaged $0.7M for the same period.
InflaRx's rule of 40 is -66168% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
InflaRx's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for InflaRx and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 506% | XXX | 169% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -27477% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -66168% | XXX | -26970% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $2K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2437% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 21331% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30073% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
InflaRx acquired XXX companies to date.
Last acquisition by InflaRx was XXXXXXXX, XXXXX XXXXX XXXXXX . InflaRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was InflaRx founded? | InflaRx was founded in 2007. |
| Where is InflaRx headquartered? | InflaRx is headquartered in United States of America. |
| How many employees does InflaRx have? | As of today, InflaRx has 74 employees. |
| Who is the CEO of InflaRx? | InflaRx's CEO is Professor Niels Riedemann. |
| Is InflaRx publicy listed? | Yes, InflaRx is a public company listed on NAS. |
| What is the stock symbol of InflaRx? | InflaRx trades under IFRX ticker. |
| When did InflaRx go public? | InflaRx went public in 2017. |
| Who are competitors of InflaRx? | Similar companies to InflaRx include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of InflaRx? | InflaRx's current market cap is $58.5M |
| What is the current revenue of InflaRx? | InflaRx's last 12 months revenue is $0.2M. |
| What is the current revenue growth of InflaRx? | InflaRx revenue growth (NTM/LTM) is 506%. |
| What is the current EV/Revenue multiple of InflaRx? | Current revenue multiple of InflaRx is 22.8x. |
| Is InflaRx profitable? | Yes, InflaRx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
